Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.74 USD
Change Today -0.13 / -3.36%
Volume 657.9K
ACRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

acelrx pharmaceuticals inc (ACRX) Snapshot

Open
$3.85
Previous Close
$3.87
Day High
$3.92
Day Low
$3.66
52 Week High
04/1/14 - $12.35
52 Week Low
03/27/15 - $3.66
Market Cap
163.5M
Average Volume 10 Days
884.5K
EPS TTM
$-0.91
Shares Outstanding
43.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACELRX PHARMACEUTICALS INC (ACRX)

acelrx pharmaceuticals inc (ACRX) Related Bloomberg News

View More Bloomberg News

acelrx pharmaceuticals inc (ACRX) Related Businessweek News

No Related Businessweek News Found

acelrx pharmaceuticals inc (ACRX) Details

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company’s lead product candidate is Zalviso, an investigational, pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in the hospital setting. The company is also developing ARX-04, a sufentanil single-dose tablet, which has been planned to initiate Phase III clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as in the emergency room, hospital floor, ambulatory care facilities, or on the battlefield. In addition, its product candidate pipeline consists of ARX-02, a pain management system that has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a single, fixed-dose, and combination drug product, which has been completed Phase II clinical trial designed to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician’s office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

50 Employees
Last Reported Date: 03/13/15
Founded in 2005

acelrx pharmaceuticals inc (ACRX) Top Compensated Officers

Chief Executive Officer, President, Chief Com...
Total Annual Compensation: $475.0K
Co-Founder, Chief Medical Officer and Directo...
Total Annual Compensation: $409.0K
Chief Engineering Officer
Total Annual Compensation: $301.0K
Compensation as of Fiscal Year 2013.

acelrx pharmaceuticals inc (ACRX) Key Developments

AcelRx Pharmaceuticals, Inc. Appoints Howard B. Rosen as Interim Chief Executive Officer, Effective April 1, 2015

AcelRx Pharmaceuticals, Inc. announced the appointment of Howard B. Rosen as interim Chief Executive Officer of AcelRx, effective April 1, 2015. Mr. Rosen is a technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Mr. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences and ALZA Corporation. Mr. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra and several private biopharmaceutical companies. In addition to the appointment of Mr. Rosen, AcelRx has restructured its work force as part of a plan to reduce operating costs and focus the company's financial and development resources on working with the U.S. Food and Drug Administration to seek marketing approval for Zalviso, as well as to continue the development of ARX-04. This restructuring will reduce the Company's workforce by 19 employees, or approximately 36% of its employee work force, and primarily impacts the commercial team and field-based medical personnel, who were hired in preparation for a potential commercial launch of Zalviso.

AcelRx Pharmaceuticals, Inc. Announces Initiation of Pivotal Phase 3 Trial for ARX-04

AcelRx Pharmaceuticals, Inc. reported dosing of the first patient in the pivotal Phase 3 study of ARX-04. ARX-04 is a non-invasive, single-use 30 mcg sufentanil sublingual tablet in a disposable, pre-filled, single-dose applicator (SDA). This study, SAP301, is a multi-center, double-blind, placebo-controlled study that will evaluate the efficacy and safety of ARX-04 versus placebo for the treatment of moderate-to-severe acute pain following ambulatory abdominal surgery. SAP301 is expected to include approximately 160 adult patients, randomized 2:1 active to placebo, to be treated for up to 48 hours. ARX-04 or placebo will be administered by site staff as requested by the patient, but no more than once per hour. The primary endpoint of the study is to demonstrate a statistically significant difference in the time-weighted summed pain intensity difference (SPID) of ARX-04 compared to placebo over a 12-hour dosing period (SPID-12). The study will be conducted at four sites in the United States.

AcelRx Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

AcelRx Pharmaceuticals, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of USD 226,000 million compared to USD 27,607,000 a year ago. Loss from operations was USD 11,779,000 compared to profit from operations of USD 19,983,000 a year ago. Net loss was USD 13,818,000 compared to net profit of USD 17,769,000 a year ago. Diluted net loss per share was USD 0.32 compared to diluted net income per share of USD 0.39 a year ago. Net loss as compared to net income in the fourth quarter last year was primarily due to the receipt of a USD 30.0 million upfront payment under the collaboration agreement with Grunenthal, of which USD 27.4 million was recognized as revenue in the fourth quarter of 2013. For the year, the company reported total revenues of USD 5,217,000 compared to USD 29,502,000 a year ago. Loss from operations was USD 37,649,000 compared to USD 6,667,000 a year ago. Net loss was USD 33,353,000 compared to USD 23,426,000 a year ago. Diluted net loss per share was USD 0.91 compared to USD 0.59 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACRX:US $3.74 USD -0.13

ACRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACRX.
View Industry Companies
 

Industry Analysis

ACRX

Industry Average

Valuation ACRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.3x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACELRX PHARMACEUTICALS INC, please visit www.acelrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.